LRMR earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -1.91. Updated 2026-07-23.
Larimar Therapeutics (LRMR) Research Hub
Larimar Therapeutics (LRMR) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.92 USD (+1.29%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.91, market cap 0.34B. This hub links to the full technical, earnings and options research available for LRMR.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.92 USD (+1.29%) |
| 52-week range | 2.96 USD – 4.47 USD |
| Trend regime | Range |
| 14-day RSI | 40.5 (Bearish) |
| Trailing P/E | -1.91 |
| Market cap | 0.34B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for LRMR
Covered Call on LRMR: how it works, illustrative setup around the real 3.92 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on LRMR: how it works, illustrative setup around the real 3.92 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on LRMR: how it works, illustrative setup around the real 3.92 USD price, max profit/loss, breakeven and when to use it. Educational.
LRMR technical analysis: range, last 3.92 USD, RSI 40.5, 52w range 2.96 USD–4.47 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is LRMR in?
Larimar Therapeutics (LRMR) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is LRMR in an uptrend or downtrend?
As of 2026-09-11, LRMR is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is LRMR's trailing P/E ratio?
LRMR's trailing P/E is -1.91, with a market cap of 0.34B. See the earnings research page for full valuation detail.
When does LRMR next report earnings?
LRMR is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.39 USD.